[S02DA03, antipyrine, Antipyrine may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[G03XB02, ulipristal, The metabolism of Ulipristal can be increased when combined with Topiramate.]
[J01GA01, streptomycin, Topiramate may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Topiramate.]
[A02BX02, sucralfate, Topiramate may decrease the excretion rate of Sucralfate which could result in a higher serum level.]
[J01CG01, sulbactam, Topiramate may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, Topiramate may decrease the excretion rate of Sulfadiazine which could result in a higher serum level.]
[J01EC01, sulfamethoxazole, Topiramate may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[M01AB02, sulindac, Sulindac may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Topiramate is combined with Sulpiride.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Topiramate is combined with Sulthiame.]
[M01AX04, apazone, Azapropazone may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[L01BB02, mercaptopurine, Topiramate may increase the excretion rate of Mercaptopurine which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be increased when combined with Topiramate.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Topiramate.]
[L01CB02, teniposide, The metabolism of Teniposide can be increased when combined with Topiramate.]
[R03CC03, terbutaline, Topiramate may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[B01AE07, dabigatran etexilate, Topiramate may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, The metabolism of Testosterone can be decreased when combined with Topiramate.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Topiramate is combined with Tetracaine.]
[S03AA02, tetracycline, Topiramate may decrease the excretion rate of Tetracycline which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Topiramate is combined with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Topiramate.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Topiramate is combined with Apomorphine.]
[L04AX02, thalidomide, Topiramate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, Topiramate may increase the excretion rate of Theobromine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, The metabolism of Theophylline can be increased when combined with Topiramate.]
[P02CA02, thiabendazole, Topiramate may decrease the excretion rate of Thiabendazole which could result in a higher serum level.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Topiramate is combined with Thiethylperazine.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be increased when combined with Topiramate.]
[N05CA19, thiopental, The metabolism of Thiopental can be decreased when combined with Topiramate.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Topiramate is combined with Thioproperazine.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Topiramate is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Topiramate is combined with Thiothixene.]
[G04BE06, moxisylyte, Topiramate may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Topiramate is combined with Tiapride.]
[B01AC05, ticlopidine, The metabolism of Ticlopidine can be decreased when combined with Topiramate.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Topiramate is combined with Tilidine.]
[S01ED01, timolol, The metabolism of Timolol can be decreased when combined with Topiramate.]
[P01AB02, tinidazole, Topiramate may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[S01AA12, tobramycin, Topiramate may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Topiramate may decrease the excretion rate of Tolazamide which could result in a higher serum level.]
[V04CA01, tolbutamide, Topiramate may decrease the excretion rate of Tolbutamide which could result in a higher serum level.]
[M02AA21, tolmetin, Tolmetin may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Topiramate is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of hyperthermia and oligohydrosis can be increased when Tramadol is combined with Topiramate.]
[N06AF04, tranylcypromine, The risk or severity of adverse effects can be increased when Topiramate is combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of adverse effects can be increased when Topiramate is combined with Trazodone.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Topiramate which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Topiramate is combined with Triazolam.]
[C03AA06, trichlormethiazide, The risk or severity of hypokalemia can be increased when Trichlormethiazide is combined with Topiramate.]
[A03AB12, mepenzolate, The risk or severity of hyperthermia and oligohydrosis can be increased when Mepenzolate is combined with Topiramate.]
[A16AX12, trientine, Topiramate may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Topiramate is combined with Trifluoperazine.]
[S01AD02, trifluridine, Topiramate may decrease the excretion rate of Trifluridine which could result in a higher serum level.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Topiramate is combined with Trifluperidol.]
[N05AA05, triflupromazine, The risk or severity of hyperthermia and oligohydrosis can be increased when Triflupromazine is combined with Topiramate.]
[N04AA01, trihexyphenidyl, The risk or severity of hyperthermia and oligohydrosis can be increased when Trihexyphenidyl is combined with Topiramate.]
[A03AA05, trimebutine, The risk or severity of hyperthermia and oligohydrosis can be increased when Trimebutine is combined with Topiramate.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Topiramate is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Topiramate is combined with Trimethadione.]
[J01EA01, trimethoprim, Topiramate may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Topiramate.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Topiramate is combined with Triprolidine.]
[A03BB01, butylscopolamine, The risk or severity of hyperthermia and oligohydrosis can be increased when Butylscopolamine is combined with Topiramate.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Topiramate is combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Topiramate.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Topiramate is combined with Tubocurarine.]
[R03DX07, roflumilast, The metabolism of Roflumilast can be increased when combined with Topiramate.]
[L01FX04, ipilimumab, Topiramate may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be increased when combined with Topiramate.]
[R02AA14, oxyquinoline, Topiramate may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[A10BH05, linagliptin, The metabolism of Linagliptin can be increased when combined with Topiramate.]
[J05AG05, rilpivirine, The serum concentration of Rilpivirine can be decreased when it is combined with Topiramate.]
[S01AA28, vancomycin, Topiramate may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Topiramate is combined with Ezogabine.]
[B01AF01, rivaroxaban, Topiramate may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[C08DA01, verapamil, The metabolism of Verapamil can be decreased when combined with Topiramate.]
[N06AX09, viloxazine, The risk or severity of adverse effects can be increased when Topiramate is combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be increased when combined with Topiramate.]
[L01CA02, vincristine, The metabolism of Vincristine can be increased when combined with Topiramate.]
[L01CA03, vindesine, The metabolism of Vindesine can be increased when combined with Topiramate.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[B01AA03, warfarin, The metabolism of Warfarin can be increased when combined with Topiramate.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Topiramate which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AF05, zuclopenthixol, The risk or severity of adverse effects can be increased when Topiramate is combined with Zuclopenthixol.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Levetiracetam is combined with Topiramate.]
[L01EC01, vemurafenib, The metabolism of Vemurafenib can be increased when combined with Topiramate.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be increased when combined with Topiramate.]
[M05BA05, tiludronic acid, Topiramate may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.]
[B06AC02, icatibant, Topiramate may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be increased when combined with Topiramate.]
[A02BC04, rabeprazole, The metabolism of Rabeprazole can be decreased when combined with Topiramate.]
[N05AE04, ziprasidone, The risk or severity of hyperthermia and oligohydrosis can be increased when Ziprasidone is combined with Topiramate.]
[G03AC10, drospirenone, The metabolism of Drospirenone can be increased when combined with Topiramate.]
[V03AC02, deferiprone, Topiramate may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, Acetylsalicylic acid may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be increased when combined with Topiramate.]
[G04BD07, tolterodine, The risk or severity of hyperthermia and oligohydrosis can be increased when Tolterodine is combined with Topiramate.]
[J01DH04, doripenem, Topiramate may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[J02AC03, voriconazole, The metabolism of Voriconazole can be decreased when combined with Topiramate.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Topiramate is combined with Atracurium.]
[S01FA01, atropine, The risk or severity of hyperthermia and oligohydrosis can be increased when Atropine is combined with Topiramate.]
[M01CB03, auranofin, Topiramate may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[L01EK01, axitinib, The metabolism of Axitinib can be increased when combined with Topiramate.]
[B03XA04, peginesatide, Topiramate may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Topiramate may decrease the excretion rate of Azacitidine which could result in a higher serum level.]
[L04AX01, azathioprine, Topiramate may decrease the excretion rate of Azathioprine which could result in a higher serum level.]
[L01BC05, gemcitabine, Topiramate may decrease the excretion rate of Gemcitabine which could result in a higher serum level.]
[J01CA09, azlocillin, The therapeutic efficacy of Topiramate can be decreased when used in combination with Azlocillin.]
[J01DF01, aztreonam, Topiramate may decrease the excretion rate of Aztreonam which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Topiramate.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Topiramate is combined with Lorcaserin.]
[G04BD12, mirabegron, Topiramate may decrease the excretion rate of Mirabegron which could result in a higher serum level.]
[L02BB04, enzalutamide, Topiramate may decrease the excretion rate of Enzalutamide which could result in a higher serum level.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be increased when combined with Topiramate.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be increased when combined with Topiramate.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Topiramate is combined with Barbital.]
[D02BA02, octinoxate, Topiramate may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Topiramate.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Topiramate is combined with Rasagiline.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Topiramate is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Topiramate is combined with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Topiramate.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Topiramate is combined with Zolmitriptan.]
[R06AC06, thonzylamine, The risk or severity of hyperthermia and oligohydrosis can be increased when Thonzylamine is combined with Topiramate.]
[G04BD10, darifenacin, The risk or severity of hyperthermia and oligohydrosis can be increased when Darifenacin is combined with Topiramate.]
[V09IX04, fluorodeoxyglucose F18, Topiramate may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Topiramate is combined with Diethyl ether.]
[V08CA11, gadofosveset, Topiramate may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be increased when combined with Topiramate.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Topiramate.]
[A16AX08, teduglutide, Topiramate may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be increased when combined with Topiramate.]
[A10BH04, alogliptin, Topiramate may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A16AX09, glycerol phenylbutyrate, Topiramate may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, The risk or severity of hypokalemia can be increased when Bendroflumethiazide is combined with Topiramate.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be increased when combined with Topiramate.]
[N02BA10, benorilate, Benorilate may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Topiramate is combined with Benperidol.]
[A10BK02, canagliflozin, Canagliflozin may increase the excretion rate of Topiramate which could result in a lower serum level and potentially a reduction in efficacy.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Topiramate is combined with Benzocaine.]
[L03AA12, ancestim, Topiramate may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, Celecoxib may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Topiramate is combined with Naratriptan.]
[L04AA18, everolimus, The metabolism of Everolimus can be increased when combined with Topiramate.]
[N04AC01, benztropine, The risk or severity of hyperthermia and oligohydrosis can be increased when Benzatropine is combined with Topiramate.]
[L01EC02, dabrafenib, The metabolism of Dabrafenib can be increased when combined with Topiramate.]
[R02AX03, benzydamine, Benzydamine may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[L01EE01, trametinib, Topiramate may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Topiramate is combined with Benzyl alcohol.]
[V09AX05, florbetapir F-18, Topiramate may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Topiramate is combined with Levomilnacipran.]
[A10BJ03, lixisenatide, Topiramate may decrease the excretion rate of Lixisenatide which could result in a higher serum level.]
[C02KX04, macitentan, Topiramate may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Topiramate is combined with Vortioxetine.]
[G03AC08, etonogestrel, The metabolism of Etonogestrel can be increased when combined with Topiramate.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Topiramate is combined with Eslicarbazepine.]
[J05AP08, sofosbuvir, Topiramate may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Topiramate is combined with Vigabatrin.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the excretion rate of Topiramate which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA27, droxidopa, Topiramate may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Topiramate is combined with Tasimelteon.]
[L04AA32, apremilast, Topiramate may decrease the excretion rate of Apremilast which could result in a higher serum level.]
[L02BG02, formestane, Topiramate may decrease the excretion rate of Formestane which could result in a higher serum level.]
[V03AB34, fomepizole, Topiramate may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be increased when combined with Topiramate.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be increased when combined with Topiramate.]
[A03BA03, hyoscyamine, The risk or severity of hyperthermia and oligohydrosis can be increased when Hyoscyamine is combined with Topiramate.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be increased when combined with Topiramate.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be increased when combined with Topiramate.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Topiramate is combined with Alfaxalone.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[D11AA01, glycopyrronium, The risk or severity of hyperthermia and oligohydrosis can be increased when Glycopyrronium is combined with Topiramate.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N05CM19, suvorexant, Topiramate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Topiramate is combined with Acepromazine.]
[N04AA02, biperiden, The risk or severity of hyperthermia and oligohydrosis can be increased when Biperiden is combined with Topiramate.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Topiramate.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be increased when combined with Topiramate.]
[S03AA06, gentamicin, Topiramate may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[L01XK01, olaparib, The metabolism of Olaparib can be increased when combined with Topiramate.]
[B01AF03, edoxaban, Topiramate may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N06AX11, mirtazapine, Topiramate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be increased when combined with Topiramate.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be increased when combined with Topiramate.]
[N02BE01, acetaminophen, Topiramate may decrease the excretion rate of Acetaminophen which could result in a higher serum level.]
[L01DC01, bleomycin, Topiramate may decrease the excretion rate of Bleomycin which could result in a higher serum level.]
[A03AA09, difemerine, The risk or severity of hyperthermia and oligohydrosis can be increased when Difemerine is combined with Topiramate.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Topiramate is combined with Brexpiprazole.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be increased when combined with Topiramate.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Topiramate is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Topiramate is combined with Cariprazine.]
[M02AA25, aceclofenac, Aceclofenac may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[M01AB11, acemetacin, Acemetacin may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Topiramate is combined with Acetazolamide.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Topiramate is combined with Acetophenazine.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be decreased when combined with Topiramate.]
[V03AB37, idarucizumab, Topiramate may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be increased when combined with Topiramate.]
[J02AC05, isavuconazole, The metabolism of Isavuconazole can be increased when combined with Topiramate.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be increased when combined with Topiramate.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Topiramate.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be increased when combined with Topiramate.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be increased when combined with Topiramate.]
[L01ED03, alectinib, The metabolism of Alectinib can be increased when combined with Topiramate.]
[M04AB05, lesinurad, Topiramate may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Topiramate is combined with Aprobarbital.]
[M01AE16, alminoprofen, Alminoprofen may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Topiramate is combined with Brivaracetam.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be increased when combined with Topiramate.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Topiramate is combined with Bromazepam.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Topiramate is combined with Bromocriptine.]
[A02AD05, aluminum magnesium silicate, Topiramate may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Topiramate is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of hyperthermia and oligohydrosis can be increased when Brompheniramine is combined with Topiramate.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Topiramate is combined with Amineptine.]
[C08CA01, amlodipine, The metabolism of Amlodipine can be increased when combined with Topiramate.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be increased when combined with Topiramate.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Topiramate is combined with Aniracetam.]
[C03CA02, bumetanide, The risk or severity of hypokalemia can be increased when Bumetanide is combined with Topiramate.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Topiramate is combined with Levobupivacaine.]
[N07BC01, buprenorphine, Topiramate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Topiramate is combined with Buspirone.]
[L01AB01, busulfan, The metabolism of Busulfan can be increased when combined with Topiramate.]
[L01XX27, arsenic trioxide, Topiramate may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[P01BE02, artemether, The metabolism of Artemether can be decreased when combined with Topiramate.]
[M02AA03, clofezone, The metabolism of Rabeprazole can be decreased when combined with Topiramate.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Topiramate is combined with Butorphanol.]
[R06AX09, azatadine, The therapeutic efficacy of Topiramate can be decreased when used in combination with Azatadine.]
[S01GX07, azelastine, Topiramate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[S01AA26, azithromycin, The metabolism of Azithromycin can be increased when combined with Topiramate.]
[L01EF02, ribociclib, The metabolism of Ribociclib can be increased when combined with Topiramate.]
[A07EC04, balsalazide, Balsalazide may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[R03DA08, bamifylline, Topiramate may increase the excretion rate of Bamifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AH05, naldemedine, Topiramate may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Topiramate may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Topiramate is combined with Beclamide.]
[N06BC01, caffeine, Topiramate may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Topiramate is combined with Oxybuprocaine.]
[P01CA02, benznidazole, Topiramate may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, The therapeutic efficacy of Topiramate can be decreased when used in combination with Linezolid.]
[J05AF06, abacavir, Topiramate may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[N07XX13, valbenazine, Topiramate may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L01EX10, midostaurin, The metabolism of Midostaurin can be increased when combined with Topiramate.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be increased when combined with Topiramate.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Topiramate is combined with Safinamide.]
[J01MA23, delafloxacin, Topiramate may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[L01BC06, capecitabine, Topiramate may decrease the excretion rate of Capecitabine which could result in a higher serum level.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be increased when combined with Topiramate.]
[L01EH02, neratinib, The metabolism of Neratinib can be increased when combined with Topiramate.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be increased when combined with Topiramate.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be increased when combined with Topiramate.]
[C07AB07, bisoprolol, Topiramate may decrease the excretion rate of Bisoprolol which could result in a higher serum level.]
[S01EC04, brinzolamide, The risk or severity of adverse effects can be increased when Topiramate is combined with Brinzolamide.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Topiramate is combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N04AA11, bornaprine, The risk or severity of hyperthermia and oligohydrosis can be increased when Bornaprine is combined with Topiramate.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Topiramate is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Topiramate is combined with Brotizolam.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Topiramate which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, Topiramate may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[M01AB07, bumadizone, Bumadizone may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be increased when combined with Topiramate.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Topiramate is combined with Butobarbital.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Topiramate is combined with Butriptyline.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Topiramate is combined with Capsaicin.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Topiramate which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Topiramate is combined with Vinylbital.]
[R06AX18, acrivastine, Topiramate may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[L02BB05, apalutamide, Topiramate may decrease the excretion rate of Apalutamide which could result in a higher serum level.]
[N03AF01, carbamazepine, The therapeutic efficacy of Topiramate can be decreased when used in combination with Carbamazepine.]
[A03AA03, camylofine, The risk or severity of hyperthermia and oligohydrosis can be increased when Camylofin is combined with Topiramate.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Topiramate is combined with Carbinoxamine.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Topiramate.]
[L04AA37, baricitinib, Topiramate may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[J01GB14, plazomicin, Topiramate may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[L01XX62, ivosidenib, The metabolism of Ivosidenib can be increased when combined with Topiramate.]
[A16AX14, migalastat, Topiramate may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The risk or severity of adverse effects can be increased when Topiramate is combined with Stiripentol.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be increased when combined with Topiramate.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be increased when combined with Topiramate.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Topiramate is combined with Cetirizine.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Topiramate is combined with Carbromal.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Topiramate is combined with Chloroprocaine.]
[D08AE05, chloroxylenol, Topiramate may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[R06AA06, chlorphenoxamine, The risk or severity of hyperthermia and oligohydrosis can be increased when Chlorphenoxamine is combined with Topiramate.]
[M01AC05, lornoxicam, Lornoxicam may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[R03DA02, oxtriphylline, Topiramate may increase the excretion rate of Oxtriphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Topiramate.]
[R03BB08, revefenacin, The risk or severity of hyperthermia and oligohydrosis can be increased when Revefenacin is combined with Topiramate.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[L01EX13, gilteritinib, The metabolism of Gilteritinib can be increased when combined with Topiramate.]
[A06AX05, prucalopride, Topiramate may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[B01AC23, cilostazol, The serum concentration of Cilostazol can be increased when it is combined with Topiramate.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Topiramate is combined with Cinitapride.]
[P02BX04, triclabendazole, The metabolism of Triclabendazole can be decreased when combined with Topiramate.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Topiramate is combined with Esketamine.]
[L04AA42, siponimod, The metabolism of Siponimod can be increased when combined with Topiramate.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Topiramate is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Topiramate is combined with Brexanolone.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be increased when combined with Topiramate.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Topiramate is combined with Clobazam.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Topiramate is combined with Cloxazolam.]
[L01EM03, alpelisib, The metabolism of Alpelisib can be increased when combined with Topiramate.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be increased when combined with Topiramate.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[J01DD01, cefotaxime, The therapeutic efficacy of Topiramate can be decreased when used in combination with Cefotaxime.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Topiramate is combined with Cyamemazine.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Topiramate which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Topiramate.]
[L01EJ02, fedratinib, The metabolism of Fedratinib can be decreased when combined with Topiramate.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be increased when combined with Topiramate.]
[N07XX11, pitolisant, Topiramate may decrease the excretion rate of Pitolisant which could result in a higher serum level.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be increased when combined with Topiramate.]
[J01XX12, lefamulin, The metabolism of Lefamulin can be increased when combined with Topiramate.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Topiramate which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Topiramate is combined with Yohimbine.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be increased when combined with Topiramate.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[J01DB03, cephalothin, The therapeutic efficacy of Topiramate can be decreased when used in combination with Cefalotin.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[G03DB05, demegestone, The metabolism of Demegestone can be increased when combined with Topiramate.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be increased when combined with Topiramate.]
[N02CC08, lasmiditan, The risk or severity of adverse effects can be increased when Lasmiditan is combined with Topiramate.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be increased when combined with Topiramate.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be increased when combined with Topiramate.]
[B06AX03, voxelotor, The metabolism of Voxelotor can be decreased when combined with Topiramate.]
[N03AX25, cenobamate, The metabolism of Cenobamate can be decreased when combined with Topiramate.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[M09AX08, golodirsen, Topiramate may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be decreased when it is combined with Topiramate.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Topiramate is combined with Dexbrompheniramine.]
[R06AB02, dexchlorpheniramine, The therapeutic efficacy of Topiramate can be decreased when used in combination with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, Topiramate may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Topiramate is combined with Dezocine.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be decreased when it is combined with Topiramate.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be increased when combined with Topiramate.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Topiramate is combined with Lumateperone.]
[N02CD06, rimegepant, The metabolism of Rimegepant can be increased when combined with Topiramate.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Topiramate is combined with Frovatriptan.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Topiramate is combined with Dichloralphenazone.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Topiramate.]
[R02AA03, dichlorobenzyl alcohol, Topiramate may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, The metabolism of Dienogest can be increased when combined with Topiramate.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Topiramate is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Topiramate is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Topiramate.]
[M01AH02, rofecoxib, Rofecoxib may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[C08CA16, clevidipine, Topiramate may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be increased when combined with Topiramate.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Topiramate is combined with Valpromide.]
[L01AA02, chlorambucil, The therapeutic efficacy of Topiramate can be decreased when used in combination with Chlorambucil.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Topiramate is combined with Chlordiazepoxide.]
[A03AA08, dihexyverine, The risk or severity of hyperthermia and oligohydrosis can be increased when Dihexyverine is combined with Topiramate.]
[L01EX17, capmatinib, The serum concentration of Capmatinib can be decreased when it is combined with Topiramate.]
[G04BD09, trospium, The risk or severity of hyperthermia and oligohydrosis can be increased when Trospium is combined with Topiramate.]
[M01AC04, droxicam, Droxicam may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[V08CA05, mangafodipir, Topiramate may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be decreased when it is combined with Topiramate.]
[M02AA27, dexketoprofen, Dexketoprofen may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Topiramate is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Topiramate is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Topiramate is combined with Dyclonine.]
[R06AX22, ebastine, The metabolism of Ebastine can be increased when combined with Topiramate.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Topiramate.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Topiramate is combined with Remimazolam.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Topiramate is combined with Oliceridine.]
[P01BA01, chloroquine, The therapeutic efficacy of Topiramate can be decreased when used in combination with Chloroquine.]
[C03AA04, chlorothiazide, The risk or severity of hypokalemia can be increased when Chlorothiazide is combined with Topiramate.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Topiramate is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The risk or severity of hyperthermia and oligohydrosis can be increased when Chlorpromazine is combined with Topiramate.]
[A10BB02, chlorpropamide, Topiramate may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.]
[N05AF03, chlorprothixene, The risk or severity of hyperthermia and oligohydrosis can be increased when Chlorprothixene is combined with Topiramate.]
[C03BA04, chlorthalidone, The risk or severity of hypokalemia can be increased when Chlorthalidone is combined with Topiramate.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Topiramate is combined with Chlorzoxazone.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Topiramate is combined with Etifoxine.]
[N02BA07, ethenzamide, Ethenzamide may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N02BA03, choline salicylate, Topiramate may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Topiramate is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Topiramate is combined with Ethyl loflazepate.]
[G03DC06, ethynodiol, The metabolism of Etynodiol can be increased when combined with Topiramate.]
[M01AB08, etodolac, Etodolac may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[M02AA06, etofenamate, Etofenamate may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[M01AX25, chondroitin sulfates, Topiramate may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Topiramate is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Topiramate is combined with Felbamate.]
[M01AE05, fenbufen, Fenbufen may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N06BA10, fenethylline, Topiramate may increase the excretion rate of Fenethylline which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA19, fenoldopam, Topiramate may decrease the excretion rate of Fenoldopam which could result in a higher serum level.]
[J01DD15, cefdinir, Topiramate may decrease the excretion rate of Cefdinir which could result in a higher serum level.]
[N02BG07, flupirtine, Topiramate may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The metabolism of Formoterol can be decreased when combined with Topiramate.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Topiramate is combined with Trichloroethylene.]
[A02BA01, cimetidine, Topiramate may decrease the excretion rate of Cimetidine which could result in a higher serum level.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Topiramate is combined with Gabapentin.]
[V08CA04, gadoteridol, Topiramate may decrease the excretion rate of Gadoteridol which could result in a higher serum level.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be increased when combined with Topiramate.]
[S03AA07, ciprofloxacin, Topiramate may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[L01XA01, cisplatin, Topiramate may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, Topiramate may increase the QTc-prolonging activities of Citalopram.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Topiramate which could result in a lower serum level and potentially a reduction in efficacy.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be decreased when combined with Topiramate.]
[L01XX74, belzutifan, The serum concentration of Belzutifan can be increased when it is combined with Topiramate.]
[V09AB03, ioflupane I-123, Topiramate may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Topiramate may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Topiramate may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Topiramate is combined with Clemastine.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be increased when combined with Topiramate.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be increased when Topiramate is combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Topiramate.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Topiramate.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Topiramate is combined with Levobupivacaine.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be increased when combined with Topiramate.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Topiramate is combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Topiramate.]
[C01EB24, mavacamten, The metabolism of Mavacamten can be decreased when combined with Topiramate.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Topiramate which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Topiramate is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Topiramate is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Topiramate is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Topiramate is combined with Granisetron.]
[N05AH02, clozapine, The risk or severity of hyperthermia and oligohydrosis can be increased when Clozapine is combined with Topiramate.]
[J01GB12, arbekacin, Topiramate may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Topiramate is combined with Halazepam.]
[S02DA02, cocaine, The risk or severity of hyperthermia and oligohydrosis can be increased when Cocaine is combined with Topiramate.]
[C02KB01, metyrosine, Topiramate may increase the sedative activities of Metyrosine.]
[M01AX13, proquazone, Proquazone may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Topiramate is combined with Codeine.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Topiramate is combined with Hexafluronium.]
[M04AC01, colchicine, Topiramate may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[A03AB10, hexocyclium, The risk or severity of hyperthermia and oligohydrosis can be increased when Hexocyclium is combined with Topiramate.]
[A03BB06, homatropine methylbromide, The risk or severity of hyperthermia and oligohydrosis can be increased when Homatropine methylbromide is combined with Topiramate.]
[J01XB01, colistin, Topiramate may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Topiramate is combined with Desflurane.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Topiramate is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Topiramate is combined with Ifenprodil.]
[A10BX03, nateglinide, Topiramate may decrease the excretion rate of Nateglinide which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[B01AC10, indobufen, Indobufen may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Topiramate is combined with Desloratadine.]
[J05AB14, valganciclovir, The therapeutic efficacy of Topiramate can be decreased when used in combination with Valganciclovir.]
[C05BB03, invert sugar, Topiramate may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Topiramate may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Topiramate may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Topiramate may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Topiramate may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, Valdecoxib may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Topiramate is combined with Almotriptan.]
[M01AH04, parecoxib, Parecoxib may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Topiramate is combined with Ketazolam.]
[M01AA06, kebuzone, Kebuzone may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[L01EA01, imatinib, The metabolism of Imatinib can be decreased when combined with Topiramate.]
[A02BC05, esomeprazole, The metabolism of Esomeprazole can be decreased when combined with Topiramate.]
[N03AX09, lamotrigine, The risk or severity of hyperthermia and oligohydrosis can be increased when Lamotrigine is combined with Topiramate.]
[N07BC04, lofexidine, The therapeutic efficacy of Topiramate can be increased when used in combination with Lofexidine.]
[M01AB09, lonazolac, Lonazolac may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Topiramate is combined with Lormetazepam.]
[H01AA02, cosyntropin, The risk or severity of liver damage can be increased when Tetracosactide is combined with Topiramate.]
[M02AA31, loxoprofen, Loxoprofen may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[C09AA03, lisinopril, Topiramate may decrease the excretion rate of Lisinopril which could result in a higher serum level.]
[A06AD01, magnesium carbonate, Topiramate may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[A03AA04, mebeverine, The risk or severity of hyperthermia and oligohydrosis can be increased when Mebeverine is combined with Topiramate.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Topiramate is combined with Medifoxamine.]
[J01DH02, meropenem, Topiramate may decrease the excretion rate of Meropenem which could result in a higher serum level.]
[R06AD04, methdilazine, The therapeutic efficacy of Topiramate can be decreased when used in combination with Methdilazine.]
[N04AA03, methixene, The risk or severity of hyperthermia and oligohydrosis can be increased when Metixene is combined with Topiramate.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Topiramate is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Topiramate is combined with Cyclobarbital.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Topiramate which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Topiramate is combined with Melperone.]
[C03AA07, cyclopenthiazide, The risk or severity of hypokalemia can be increased when Cyclopenthiazide is combined with Topiramate.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be increased when combined with Topiramate.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Topiramate is combined with Minaprine.]
[S01XA18, cyclosporine, The metabolism of Cyclosporine can be increased when combined with Topiramate.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Topiramate is combined with Moclobemide.]
[R06AX02, cyproheptadine, The risk or severity of hyperthermia and oligohydrosis can be increased when Cyproheptadine is combined with Topiramate.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be increased when combined with Topiramate.]
[M02AA02, mofebutazone, Mofebutazone may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[M01AX22, morniflumate, Morniflumate may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[C03XA02, conivaptan, The metabolism of Conivaptan can be increased when combined with Topiramate.]
[M01AH05, etoricoxib, Etoricoxib may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[L01AX04, dacarbazine, Topiramate may decrease the excretion rate of Dacarbazine which could result in a higher serum level.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Topiramate is combined with Dantrolene.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Topiramate is combined with Deanol.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Topiramate.]
[M01AX01, nabumetone, Nabumetone may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N07BB05, nalmefene, Topiramate may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Topiramate is combined with Nordazepam.]
[C07AB12, nebivolol, The metabolism of Nebivolol can be decreased when combined with Topiramate.]
[S01GX04, nedocromil, Topiramate may decrease the excretion rate of Nedocromil which could result in a higher serum level.]
[N06AX06, nefazodone, The risk or severity of adverse effects can be increased when Topiramate is combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Topiramate is combined with Niaprazine.]
[C01DX16, nicorandil, Topiramate may decrease the excretion rate of Nicorandil which could result in a higher serum level.]
[L02BB02, nilutamide, The metabolism of Nilutamide can be decreased when combined with Topiramate.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Topiramate is combined with Tiagabine.]
[G03DB04, nomegestrol, The metabolism of Nomegestrol can be increased when combined with Topiramate.]
[C01CA23, theodrenaline, Topiramate may increase the excretion rate of Theodrenaline which could result in a lower serum level and potentially a reduction in efficacy.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Topiramate is combined with Cisatracurium.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Topiramate is combined with Normethadone.]
[B01AX05, fondaparinux, Topiramate may decrease the excretion rate of Fondaparinux which could result in a higher serum level.]
[N06AB10, escitalopram, The risk or severity of hyperthermia and oligohydrosis can be increased when Escitalopram is combined with Topiramate.]
[G04BD08, solifenacin, The risk or severity of hyperthermia and oligohydrosis can be increased when Solifenacin is combined with Topiramate.]
[A07EC03, olsalazine, Olsalazine may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N06AA01, desipramine, The risk or severity of hyperthermia and oligohydrosis can be increased when Desipramine is combined with Topiramate.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[V04CH02, indigo carmine, Topiramate may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Topiramate may decrease the excretion rate of Ertapenem which could result in a higher serum level.]
[M01AE12, oxaprozin, Oxaprozin may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Topiramate is combined with Oxcarbazepine.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Topiramate is combined with Oxiracetam.]
[N04AA08, dexetimide, The risk or severity of hyperthermia and oligohydrosis can be increased when Dexetimide is combined with Topiramate.]
[G04BD04, oxybutynin, The risk or severity of hyperthermia and oligohydrosis can be increased when Oxybutynin is combined with Topiramate.]
[A03AA01, oxyphencyclimine, The risk or severity of hyperthermia and oligohydrosis can be increased when Oxyphencyclimine is combined with Topiramate.]
[N06BA02, dextroamphetamine, The therapeutic efficacy of Topiramate can be decreased when used in combination with Amphetamine.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Topiramate is combined with Dextromethorphan.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Topiramate is combined with Paramethadione.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Topiramate is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of hyperthermia and oligohydrosis can be increased when Paroxetine is combined with Topiramate.]
[B01AC04, clopidogrel, The metabolism of Clopidogrel can be decreased when combined with Topiramate.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Topiramate is combined with Diamorphine.]
[C04AD01, pentifylline, Topiramate may increase the excretion rate of Pentifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[P03AC04, permethrin, Topiramate may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Topiramate is combined with Diazepam.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Topiramate is combined with Phenacemide.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Topiramate is combined with Phenol.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Topiramate is combined with Phensuximide.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Topiramate is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Topiramate is combined with Cinchocaine.]
[R05DA08, pholcodine, Topiramate may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, The risk or severity of adverse effects can be increased when Topiramate is combined with Diclofenamide.]
[S01BC03, diclofenac, Diclofenac may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[A03AA07, dicyclomine, The risk or severity of hyperthermia and oligohydrosis can be increased when Dicyclomine is combined with Topiramate.]
[J05AF02, didanosine, Topiramate may decrease the excretion rate of Didanosine which could result in a higher serum level.]
[A10BG03, pioglitazone, The serum concentration of Pioglitazone can be decreased when it is combined with Topiramate.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Topiramate is combined with Pipamperone.]
[A03AB14, pipenzolate, The risk or severity of hyperthermia and oligohydrosis can be increased when Pipenzolate is combined with Topiramate.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be increased when combined with Topiramate.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be increased when combined with Topiramate.]
[C03CA03, piretanide, The risk or severity of hypokalemia can be increased when Piretanide is combined with Topiramate.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Topiramate is combined with Diethylpropion.]
[L02AA01, diethylstilbestrol, The metabolism of Diethylstilbestrol can be increased when combined with Topiramate.]
[C08CA03, isradipine, Isradipine may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[D07XC04, diflucortolone, Topiramate may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A03AB11, poldine, The risk or severity of hyperthermia and oligohydrosis can be increased when Poldine is combined with Topiramate.]
[N02BA11, diflunisal, Diflunisal may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be increased when combined with Topiramate.]
[C01AA05, digoxin, Topiramate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C04AE04, dihydroergocristine, The metabolism of Dihydroergocristine can be increased when combined with Topiramate.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be increased when combined with Topiramate.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Topiramate is combined with Hydromorphone.]
[L04AX04, lenalidomide, Topiramate may decrease the excretion rate of Lenalidomide which could result in a higher serum level.]
[J05AE08, atazanavir, The metabolism of Atazanavir can be increased when combined with Topiramate.]
[H03BC01, potassium perchlorate, Topiramate may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Topiramate may decrease the excretion rate of Pralidoxime which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Topiramate is combined with Pramocaine.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Topiramate is combined with Dimenhydrinate.]
[V03AB09, dimercaprol, Topiramate may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Topiramate is combined with Pridinol.]
[R06AB03, dimethindene, The risk or severity of hyperthermia and oligohydrosis can be increased when Dimetindene is combined with Topiramate.]
[M02AX03, dimethyl sulfoxide, Topiramate may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Topiramate is combined with Progabide.]
[N06BC02, propentofylline, Topiramate may increase the excretion rate of Propentofylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BB04, propyphenazone, Propyphenazone may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[M01AB14, proglumetacin, Proglumetacin may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Topiramate is combined with Proparacaine.]
[R03DA03, proxyphylline, Topiramate may increase the excretion rate of Proxyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AA02, diphenhydramine, The risk or severity of hyperthermia and oligohydrosis can be increased when Diphenhydramine is combined with Topiramate.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Topiramate is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Topiramate is combined with Quazepam.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Topiramate is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Topiramate is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of adverse effects can be increased when Topiramate is combined with Cisapride.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be increased when combined with Topiramate.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Topiramate is combined with Remoxipride.]
[S01AX06, resorcinol, Topiramate may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, The risk or severity of hyperthermia and oligohydrosis can be increased when Disopyramide is combined with Topiramate.]
[P03AA04, disulfiram, The therapeutic efficacy of Topiramate can be decreased when used in combination with Disulfiram.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Topiramate is combined with Riluzole.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Topiramate is combined with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Topiramate is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Topiramate is combined with Ropivacaine.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be increased when combined with Topiramate.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be increased when combined with Topiramate.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be increased when combined with Topiramate.]
[G04BE08, tadalafil, Topiramate may decrease the excretion rate of Tadalafil which could result in a higher serum level.]
[S01BC05, ketorolac, Ketorolac may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[C01EB18, ranolazine, Ranolazine may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N02BA06, salsalate, Salsalate may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[C01CA07, dobutamine, Topiramate may decrease the excretion rate of Dobutamine which could result in a higher serum level.]
[C01CA04, dopamine, Topiramate may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N06AA16, dothiepin, The risk or severity of hyperthermia and oligohydrosis can be increased when Dosulepin is combined with Topiramate.]
[N06AA12, doxepin, The risk or severity of hyperthermia and oligohydrosis can be increased when Doxepin is combined with Topiramate.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be increased when combined with Topiramate.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Topiramate.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Topiramate is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Topiramate is combined with Sevoflurane.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Topiramate.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Topiramate is combined with Sibutramine.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Topiramate can be decreased when used in combination with Sodium phosphate, monobasic.]
[A12CA02, sodium sulfate, Topiramate may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[R03DA01, dyphylline, Topiramate may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Topiramate is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Topiramate is combined with Sumatriptan.]
[V04CX07, edrophonium, Topiramate may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[L01AX03, temozolomide, Topiramate may decrease the excretion rate of Temozolomide which could result in a higher serum level.]
[M01AC02, tenoxicam, Tenoxicam may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[A08AB01, orlistat, Orlistat can cause a decrease in the absorption of Topiramate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Topiramate is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Topiramate is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Topiramate is combined with Thiopropazate.]
[G04BD01, emepronium, The risk or severity of hyperthermia and oligohydrosis can be increased when Emepronium is combined with Topiramate.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be increased when combined with Topiramate.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Topiramate is combined with Tofisopam.]
[M01AG02, tolfenamic acid, Tolfenamic acid may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Topiramate is combined with Toloxatone.]
[N06BA09, atomoxetine, Topiramate may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[N07XX04, sodium oxybate, Topiramate may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[S02BA08, fluocinolone acetonide, Topiramate may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.]
[M01AG01, mefenamic acid, Mefenamic acid may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[C01DA05, pentaerythritol tetranitrate, Topiramate may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[C03CA04, torsemide, The risk or severity of hypokalemia can be increased when Torasemide is combined with Topiramate.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Topiramate is combined with Loprazolam.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Topiramate is combined with Triclofos.]
[A03AB08, tridihexethyl, The risk or severity of hyperthermia and oligohydrosis can be increased when Tridihexethyl is combined with Topiramate.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Topiramate is combined with Trimethobenzamide.]
[N04AA12, tropatepine, The risk or severity of hyperthermia and oligohydrosis can be increased when Tropatepine is combined with Topiramate.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Topiramate.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Topiramate is combined with Urapidil.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Topiramate is combined with Veralipride.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be increased when combined with Topiramate.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Topiramate is combined with Epinastine.]
[N06AX16, venlafaxine, The risk or severity of adverse effects can be increased when Topiramate is combined with Venlafaxine.]
[N05CF02, zolpidem, Topiramate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, Zomepirac may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Topiramate is combined with Zonisamide.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Topiramate is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Topiramate is combined with Zotepine.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Topiramate is combined with Guanfacine.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Topiramate is combined with Moricizine.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Topiramate is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Topiramate is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The metabolism of Ergotamine can be increased when combined with Topiramate.]
[L03AX05, pidotimod, Topiramate may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Topiramate is combined with Estazolam.]
[A02BC02, pantoprazole, The metabolism of Pantoprazole can be decreased when combined with Topiramate.]
[G03CA03, estradiol, The metabolism of Estradiol can be increased when combined with Topiramate.]
[G03CA57, estrogens, conjugated (USP), Topiramate may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.]
[J04AK02, ethambutol, Topiramate may decrease the excretion rate of Ethambutol which could result in a higher serum level.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Topiramate.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be increased when combined with Topiramate.]
[C01BD05, ibutilide, Topiramate may decrease the excretion rate of Ibutilide which could result in a higher serum level.]
[N04AA05, profenamine, The risk or severity of hyperthermia and oligohydrosis can be increased when Profenamine is combined with Topiramate.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Topiramate is combined with Ethosuximide.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Topiramate is combined with Ethotoin.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Topiramate is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Topiramate is combined with Meloxicam.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Topiramate is combined with Ethylmorphine.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Topiramate is combined with Etidocaine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Topiramate is combined with Etomidate.]
[L01CB01, etoposide, The metabolism of Etoposide can be increased when combined with Topiramate.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Topiramate is combined with Sertindole.]
[L04AD02, tacrolimus, The metabolism of Tacrolimus can be increased when combined with Topiramate.]
[R06AX11, astemizole, The metabolism of Astemizole can be increased when combined with Topiramate.]
[R06AX12, terfenadine, The risk or severity of hyperthermia and oligohydrosis can be increased when Terfenadine is combined with Topiramate.]
[P01AX07, trimetrexate, Topiramate may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Topiramate is combined with Bupropion.]
[N06AB08, fluvoxamine, The risk or severity of adverse effects can be increased when Topiramate is combined with Fluvoxamine.]
[L02AE02, leuprolide, Leuprolide may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[M01CB01, gold sodium thiomalate, Topiramate may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Topiramate may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Topiramate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.]
[A16AA01, levocarnitine, Topiramate may decrease the excretion rate of Levocarnitine which could result in a higher serum level.]
[P02CA03, albendazole, The metabolism of Albendazole can be increased when combined with Topiramate.]
[N03AX26, fenfluramine, The risk or severity of adverse effects can be increased when Topiramate is combined with Fenfluramine.]
[M01AE04, fenoprofen, Fenoprofen may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Topiramate is combined with Fentanyl.]
[R03CC02, albuterol, Topiramate may decrease the excretion rate of Salbutamol which could result in a higher serum level.]
[L01BB06, clofarabine, Topiramate may decrease the excretion rate of Clofarabine which could result in a higher serum level.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[G04BD02, flavoxate, The risk or severity of hyperthermia and oligohydrosis can be increased when Flavoxate is combined with Topiramate.]
[N02BG04, floctafenine, Floctafenine may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[J02AC01, fluconazole, Fluconazole may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[J02AX01, flucytosine, Topiramate may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[V03AB25, flumazenil, Topiramate may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Topiramate is combined with Flunarizine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Topiramate is combined with Flunitrazepam.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Topiramate is combined with Melitracen.]
[V03AZ01, ethanol, Ethanol may increase the central nervous system depressant (CNS depressant) activities of Topiramate.]
[L01BC09, floxuridine, Topiramate may decrease the excretion rate of Floxuridine which could result in a higher serum level.]
[N06AB03, fluoxetine, Topiramate may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of hyperthermia and oligohydrosis can be increased when Flupentixol is combined with Topiramate.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Topiramate is combined with Fluphenazine.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Topiramate is combined with Flurazepam.]
[S01BC04, flurbiprofen, Flurbiprofen may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Topiramate is combined with Fluspirilene.]
[L02BB01, flutamide, Topiramate may decrease the excretion rate of Flutamide which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[S02AA17, fosfomycin, Topiramate may decrease the excretion rate of Fosfomycin which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[L01BC03, tegafur, Topiramate may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Topiramate is combined with Alcuronium.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Topiramate is combined with Furazolidone.]
[C03CA01, furosemide, The risk or severity of hypokalemia can be increased when Furosemide is combined with Topiramate.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Topiramate is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Topiramate is combined with Amisulpride.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Topiramate is combined with Gallamine.]
[S01AD09, ganciclovir, The therapeutic efficacy of Topiramate can be decreased when used in combination with Ganciclovir.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Topiramate is combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Topiramate is combined with Bifemelane.]
[C10AB04, gemfibrozil, Topiramate may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.]
[J01XA03, telavancin, Topiramate may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be increased when combined with Topiramate.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be increased when combined with Topiramate.]
[C01CA21, cafedrine, Topiramate may increase the excretion rate of Cafedrine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AG04, etravirine, The metabolism of Etravirine can be decreased when combined with Topiramate.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Topiramate is combined with Methsuximide.]
[G03XA02, gestrinone, The metabolism of Gestrinone can be increased when combined with Topiramate.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Topiramate is combined with Alfentanil.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be decreased when combined with Topiramate.]
[A10BB01, glyburide, The serum concentration of Glyburide can be decreased when it is combined with Topiramate.]
[A10BB09, gliclazide, The metabolism of Gliclazide can be decreased when combined with Topiramate.]
[A10BB07, glipizide, Topiramate may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Topiramate is combined with Dexmedetomidine.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Topiramate is combined with Glutethimide.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be increased when combined with Topiramate.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be increased when combined with Topiramate.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be increased when combined with Topiramate.]
[M01CB04, aurothioglucose, Topiramate may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Topiramate may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[C09AA09, fosinopril, Topiramate may decrease the excretion rate of Fosinopril which could result in a higher serum level.]
[S01EX01, guanethidine, Topiramate may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, Goserelin may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[P01BX01, halofantrine, The therapeutic efficacy of Topiramate can be decreased when used in combination with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Topiramate.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Topiramate is combined with Halothane.]
[N05AH04, quetiapine, The risk or severity of hyperthermia and oligohydrosis can be increased when Quetiapine is combined with Topiramate.]
[N06BX13, idebenone, Topiramate may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Topiramate is combined with Iprazochrome.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be increased when combined with Topiramate.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Topiramate is combined with Allobarbital.]
[M04AA01, allopurinol, Topiramate may decrease the excretion rate of Allopurinol which could result in a higher serum level.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be increased when combined with Topiramate.]
[A07EC02, mesalamine, Mesalazine may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Topiramate is combined with Hexobarbital.]
[M02AA26, nimesulide, Nimesulide may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[C09AA04, perindopril, Topiramate may decrease the excretion rate of Perindopril which could result in a higher serum level.]
[C02DB02, hydralazine, Topiramate may decrease the excretion rate of Hydralazine which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, The risk or severity of hypokalemia can be increased when Hydrochlorothiazide is combined with Topiramate.]
[R05DA03, hydrocodone, Topiramate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[C03AA02, hydroflumethiazide, The risk or severity of hypokalemia can be increased when Hydroflumethiazide is combined with Topiramate.]
[B05XA17, potassium acetate, Topiramate may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Topiramate which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[G04BD06, propiverine, The risk or severity of hyperthermia and oligohydrosis can be increased when Propiverine is combined with Topiramate.]
[P01BA02, hydroxychloroquine, The therapeutic efficacy of Topiramate can be decreased when used in combination with Hydroxychloroquine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Topiramate is combined with Prothipendyl.]
[B05AA07, hetastarch, Topiramate may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Topiramate.]
[R02AX02, ibuprofen, Ibuprofen may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[B05XA08, sodium acetate, Topiramate may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be increased when combined with Topiramate.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Topiramate is combined with Sufentanil.]
[N06AA02, imipramine, The risk or severity of hyperthermia and oligohydrosis can be increased when Imipramine is combined with Topiramate.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be increased when combined with Topiramate.]
[R01AD07, tixocortol, Topiramate may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Topiramate is combined with Tizanidine.]
[L01CE01, topotecan, Topiramate may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA11, indapamide, The risk or severity of hypokalemia can be increased when Indapamide is combined with Topiramate.]
[S01BC01, indomethacin, Indomethacin may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[A11HA07, inositol, Topiramate may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Topiramate is combined with Milnacipran.]
[A03AA30, piperidolate, The risk or severity of hyperthermia and oligohydrosis can be increased when Piperidolate is combined with Topiramate.]
[S01XA28, varenicline, Topiramate may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Topiramate is combined with Articaine.]
[A10BH01, sitagliptin, Topiramate may decrease the excretion rate of Sitagliptin which could result in a higher serum level.]
[V08AB02, iohexol, The therapeutic efficacy of Topiramate can be decreased when used in combination with Iohexol.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Topiramate is combined with Alprazolam.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Topiramate is combined with Ramelteon.]
[R06AE01, buclizine, The risk or severity of hyperthermia and oligohydrosis can be increased when Buclizine is combined with Topiramate.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Topiramate is combined with Alprenolol.]
[C03BA02, quinethazone, The risk or severity of hypokalemia can be increased when Quinethazone is combined with Topiramate.]
[V03AB01, ipecac, Topiramate may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Topiramate is combined with Iprindole.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Topiramate is combined with Iproniazid.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Topiramate is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Topiramate is combined with Isocarboxazid.]
[S01EC03, dorzolamide, The risk or severity of adverse effects can be increased when Topiramate is combined with Dorzolamide.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Topiramate is combined with Isoflurane.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Topiramate is combined with Entacapone.]
[J04AC01, isoniazid, The therapeutic efficacy of Topiramate can be decreased when used in combination with Isoniazid.]
[J05AX05, inosine pranobex, Topiramate may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[D10BA01, isotretinoin, Topiramate may decrease the excretion rate of Isotretinoin which could result in a higher serum level.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Topiramate.]
[S01AA24, kanamycin, Topiramate may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Topiramate is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Topiramate is combined with Ketanserin.]
[B01AC22, prasugrel, Topiramate may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[N05AH03, olanzapine, The risk or severity of hyperthermia and oligohydrosis can be increased when Olanzapine is combined with Topiramate.]
[M02AA10, ketoprofen, Ketoprofen may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N04BC09, rotigotine, Topiramate may increase the sedative activities of Rotigotine.]
[J01MB02, nalidixic acid, The therapeutic efficacy of Topiramate can be decreased when used in combination with Nalidixic acid.]
[C07AG01, labetalol, The metabolism of Labetalol can be decreased when combined with Topiramate.]
[N04BB01, amantadine, Topiramate may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[A06AX03, lubiprostone, Topiramate may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Topiramate is combined with Lacosamide.]
[C03CC01, ethacrynic acid, The risk or severity of hypokalemia can be increased when Etacrynic acid is combined with Topiramate.]
[G03AD01, levonorgestrel, The metabolism of Levonorgestrel can be increased when combined with Topiramate.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Topiramate is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Topiramate is combined with Lidocaine.]
[S01AA21, amikacin, Topiramate may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Topiramate which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Topiramate is combined with Lisuride.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Topiramate is combined with Lofepramine.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Topiramate.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Topiramate is combined with Loxapine.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be increased when combined with Topiramate.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be increased when combined with Topiramate.]
[B05XA11, magnesium chloride, Topiramate may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Topiramate may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Topiramate can be increased when used in combination with Magnesium sulfate.]
[L01BA05, pralatrexate, Topiramate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The metabolism of Nilotinib can be increased when combined with Topiramate.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Topiramate which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, The risk or severity of hyperthermia and oligohydrosis can be increased when Maprotiline is combined with Topiramate.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Topiramate is combined with Mazindol.]
[C02BB01, mecamylamine, Topiramate may decrease the excretion rate of Mecamylamine which could result in a higher serum level.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Topiramate is combined with Meclizine.]
[M02AA18, meclofenamic acid, Meclofenamic acid may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Topiramate is combined with Medazepam.]
[P01BC02, mefloquine, The therapeutic efficacy of Topiramate can be decreased when used in combination with Mefloquine.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Topiramate which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Topiramate is combined with Melatonin.]
[N06DX01, memantine, Topiramate may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Topiramate is combined with Meperidine.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Topiramate is combined with Mephenytoin.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Topiramate is combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Topiramate is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Topiramate is combined with Meprobamate.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Topiramate is combined with Meptazinol.]
[G04BX16, tiopronin, Topiramate may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Topiramate which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Topiramate is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of adverse effects can be increased when Topiramate is combined with Paliperidone.]
[A10BA02, metformin, The risk or severity of adverse effects can be increased when Topiramate is combined with Metformin.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Topiramate is combined with Dolasetron.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Topiramate.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Topiramate is combined with Metamfetamine.]
[A03AB07, methantheline, The risk or severity of hyperthermia and oligohydrosis can be increased when Methantheline is combined with Topiramate.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Topiramate is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Topiramate is combined with Methaqualone.]
[J05AF05, lamivudine, Topiramate may decrease the excretion rate of Lamivudine which could result in a higher serum level.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Topiramate is combined with Metharbital.]
[S01EC05, methazolamide, The risk or severity of adverse effects can be increased when Topiramate is combined with Methazolamide.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Topiramate is combined with Metergoline.]
[H03BB02, methimazole, Topiramate may decrease the excretion rate of Methimazole which could result in a higher serum level.]
[L01BA04, pemetrexed, Topiramate may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Topiramate is combined with Methocarbamol.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Topiramate is combined with Methohexital.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Topiramate is combined with Ziconotide.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be increased when combined with Topiramate.]
[N05AA02, methotrimeprazine, The risk or severity of hyperthermia and oligohydrosis can be increased when Methotrimeprazine is combined with Topiramate.]
[D05BA02, methoxsalen, Topiramate may decrease the excretion rate of Methoxsalen which could result in a higher serum level.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Topiramate is combined with Methoxyflurane.]
[C03AA08, methyclothiazide, The risk or severity of hypokalemia can be increased when Methyclothiazide is combined with Topiramate.]
[C02AB01, methyldopa, Topiramate may decrease the excretion rate of Methyldopa which could result in a higher serum level.]
[V04CG05, methylene blue, The risk or severity of adverse effects can be increased when Topiramate is combined with Methylene blue.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be increased when combined with Topiramate.]
[N06BA04, methylphenidate, The therapeutic efficacy of Topiramate can be decreased when used in combination with Methylphenidate.]
[N03AF03, rufinamide, The serum concentration of Topiramate can be increased when it is combined with Rufinamide.]
[G03EK01, methyltestosterone, Topiramate may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Topiramate is combined with Methyprylon.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Topiramate.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Topiramate.]
[C03BA08, metolazone, The risk or severity of hypokalemia can be increased when Metolazone is combined with Topiramate.]
[C07AB02, metoprolol, Metoprolol may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[P01AB01, metronidazole, The therapeutic efficacy of Topiramate can be decreased when used in combination with Metronidazole.]
[V04CD01, metyrapone, Topiramate may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[N06AX03, mianserin, The therapeutic efficacy of Topiramate can be decreased when used in combination with Mianserin.]
[N02BB03, aminopyrine, Aminophenazone may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Topiramate is combined with Midazolam.]
[G03XB01, mifepristone, The metabolism of Mifepristone can be increased when combined with Topiramate.]
[J05AH01, zanamivir, Topiramate may decrease the excretion rate of Zanamivir which could result in a higher serum level.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Topiramate.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Topiramate is combined with Molindone.]
[L03AC01, aldesleukin, Aldesleukin may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[C01BD01, amiodarone, The metabolism of Amiodarone can be increased when combined with Topiramate.]
[N06AA09, amitriptyline, The risk or severity of hyperthermia and oligohydrosis can be increased when Amitriptyline is combined with Topiramate.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Topiramate is combined with Morphine.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Topiramate is combined with Palonosetron.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[L04AB05, certolizumab pegol, Topiramate may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.]
[G04BA01, ammonium chloride, Topiramate may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be increased when combined with Topiramate.]
[L04AA06, mycophenolic acid, Topiramate may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Topiramate is combined with Vecuronium.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Topiramate is combined with Amobarbital.]
[N06AA17, amoxapine, The risk or severity of hyperthermia and oligohydrosis can be increased when Amoxapine is combined with Topiramate.]
[N03AB05, fosphenytoin, The serum concentration of the active metabolites of Fosphenytoin can be increased when Fosphenytoin is used in combination with Topiramate.]
[C07AA12, nadolol, Topiramate may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01CA04, amoxicillin, Topiramate may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[N04BC04, ropinirole, Topiramate may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Topiramate is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Topiramate is combined with Nalbuphine.]
[V03AB15, naloxone, Topiramate may decrease the excretion rate of Naloxone which could result in a higher serum level.]
[N06BA01, amphetamine, The therapeutic efficacy of Topiramate can be decreased when used in combination with Amphetamine.]
[M02AA12, naproxen, Naproxen may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Topiramate is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Topiramate is combined with Tolcapone.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be increased when combined with Topiramate.]
[S03AA01, neomycin, Topiramate may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Topiramate is combined with Remifentanil.]
[B01AC17, tirofiban, Topiramate may decrease the excretion rate of Tirofiban which could result in a higher serum level.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Topiramate is combined with Iloperidone.]
[J02AA01, amphotericin B, The therapeutic efficacy of Topiramate can be decreased when used in combination with Amphotericin B.]
[S01AA19, ampicillin, Topiramate may decrease the excretion rate of Ampicillin which could result in a higher serum level.]
[L03AX16, plerixafor, Topiramate may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Topiramate may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Topiramate is combined with Desvenlafaxine.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[C01CE01, inamrinone, Topiramate may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Topiramate is combined with Nialamide.]
[C08CA04, nicardipine, The risk or severity of hyperthermia and oligohydrosis can be increased when Nicardipine is combined with Topiramate.]
[C08CA05, nifedipine, Topiramate may decrease the excretion rate of Nifedipine which could result in a higher serum level.]
[M02AA17, niflumic acid, Niflumic acid may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[C08CA07, nisoldipine, Topiramate may decrease the excretion rate of Nisoldipine which could result in a higher serum level.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Topiramate is combined with Nitrazepam.]
[R07AX01, nitric oxide, Topiramate may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Topiramate may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Topiramate is combined with Zaleplon.]
[N04BC05, pramipexole, Topiramate may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, Topiramate may decrease the excretion rate of Nitroprusside which could result in a higher serum level.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Topiramate is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Topiramate is combined with Nomifensine.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be increased when combined with Topiramate.]
[G03AC07, norgestrienone, The metabolism of Norgestrienone can be increased when combined with Topiramate.]
[N06AA10, nortriptyline, The risk or severity of hyperthermia and oligohydrosis can be increased when Nortriptyline is combined with Topiramate.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be decreased when combined with Topiramate.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Topiramate is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Topiramate is combined with Opium.]
[G04CA02, tamsulosin, Topiramate may decrease the excretion rate of Tamsulosin which could result in a higher serum level.]
[J01CF04, oxacillin, Topiramate may decrease the excretion rate of Oxacillin which could result in a higher serum level.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Topiramate is combined with Oxazepam.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Topiramate is combined with Oxprenolol.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Topiramate is combined with Oxycodone.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Topiramate is combined with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Topiramate is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[A03AB03, oxyphenonium, The risk or severity of hyperthermia and oligohydrosis can be increased when Oxyphenonium is combined with Topiramate.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Topiramate is combined with Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Topiramate.]
[M03AC01, pancuronium, The risk or severity of hyperthermia and oligohydrosis can be increased when Pancuronium is combined with Topiramate.]
[J04AB30, capreomycin, Topiramate may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G03DB06, chlormadinone, The metabolism of Chlormadinone can be increased when combined with Topiramate.]
[N05CC05, paraldehyde, Topiramate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Topiramate is combined with Pargyline.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[G04BD11, fesoterodine, The risk or severity of hyperthermia and oligohydrosis can be increased when Fesoterodine is combined with Topiramate.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Topiramate is combined with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Topiramate is combined with Penfluridol.]
[J01CE09, penicillin G procaine, Topiramate may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Topiramate is combined with Pentazocine.]
[N05CA01, pentobarbital, The risk or severity of adverse effects can be increased when Topiramate is combined with Pentobarbital.]
[L01XX08, pentostatin, Topiramate may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Topiramate may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Topiramate is combined with Perazine.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Topiramate is combined with Pergolide.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Topiramate is combined with Perphenazine.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Topiramate is combined with Phenazocine.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Topiramate is combined with Phenelzine.]
[N03AA02, phenobarbital, The metabolism of Phenobarbital can be decreased when combined with Topiramate.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Topiramate is combined with Phenoperidine.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be increased when combined with Topiramate.]
[V03AB36, phentolamine, Topiramate may decrease the excretion rate of Phentolamine which could result in a higher serum level.]
[M02AA01, phenylbutazone, Phenylbutazone may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[A02BC06, dexlansoprazole, The metabolism of Dexlansoprazole can be decreased when combined with Topiramate.]
[R01BA01, phenylpropanolamine, The therapeutic efficacy of Topiramate can be decreased when used in combination with Phenylpropanolamine.]
[N03AB02, phenytoin, The serum concentration of the active metabolites of Phenytoin can be increased when Phenytoin is used in combination with Topiramate.]
[S01AE05, levofloxacin, Topiramate may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be increased when combined with Topiramate.]
[B02BA01, vitamin K1, Topiramate may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N05AG02, pimozide, The metabolism of Pimozide can be increased when combined with Topiramate.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Topiramate is combined with Pindolol.]
[J01CA12, piperacillin, Topiramate may decrease the excretion rate of Piperacillin which could result in a higher serum level.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Topiramate is combined with Pipotiazine.]
[N06BX03, piracetam, Topiramate may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[A02BX03, pirenzepine, The risk or severity of hyperthermia and oligohydrosis can be increased when Pirenzepine is combined with Topiramate.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Topiramate is combined with Piritramide.]
[S01BC06, piroxicam, Piroxicam may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[N02CX01, pizotyline, The risk or severity of hyperthermia and oligohydrosis can be increased when Pizotifen is combined with Topiramate.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Topiramate is combined with Proxibarbal.]
[A10BG02, rosiglitazone, Topiramate may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Topiramate is combined with Alosetron.]
[C03AA05, polythiazide, The risk or severity of hypokalemia can be increased when Polythiazide is combined with Topiramate.]
[A10BH03, saxagliptin, Topiramate may decrease the excretion rate of Saxagliptin which could result in a higher serum level.]
[B05XA01, potassium chloride, Topiramate may decrease the excretion rate of Potassium chloride which could result in a higher serum level.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Topiramate is combined with Prazepam.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Topiramate.]
[H02AB07, prednisone, Topiramate may decrease the excretion rate of Prednisone which could result in a higher serum level.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Topiramate is combined with Prilocaine.]
[N03AA03, primidone, The risk or severity of adverse effects can be increased when Topiramate is combined with Primidone.]
[M04AB01, probenecid, Topiramate may decrease the excretion rate of Probenecid which could result in a higher serum level.]
[C01BA02, procainamide, Topiramate may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Topiramate is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Topiramate is combined with Procarbazine.]
[C10AB05, fenofibrate, The metabolism of Fenofibrate can be increased when combined with Topiramate.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Topiramate is combined with Prochlorperazine.]
[N04AA04, procyclidine, The risk or severity of hyperthermia and oligohydrosis can be increased when Procyclidine is combined with Topiramate.]
[G03DA04, progesterone, The metabolism of Progesterone can be increased when combined with Topiramate.]
[N05AA03, promazine, The risk or severity of hyperthermia and oligohydrosis can be increased when Promazine is combined with Topiramate.]
[R06AD02, promethazine, The risk or severity of hyperthermia and oligohydrosis can be increased when Promethazine is combined with Topiramate.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Topiramate is combined with Propanidid.]
[A03AB05, propantheline, The risk or severity of hyperthermia and oligohydrosis can be increased when Propantheline is combined with Topiramate.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Topiramate is combined with Periciazine.]
[N05CM06, propiomazine, The risk or severity of hyperthermia and oligohydrosis can be increased when Propiomazine is combined with Topiramate.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be increased when combined with Topiramate.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Topiramate is combined with Propofol.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Topiramate is combined with Dextropropoxyphene.]
[C07AA05, propranolol, The serum concentration of Propranolol can be increased when it is combined with Topiramate.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Topiramate is combined with Rizatriptan.]
[B01AC09, epoprostenol, Topiramate may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Topiramate is combined with Protriptyline.]
[N05AX12, aripiprazole, The risk or severity of hyperthermia and oligohydrosis can be increased when Aripiprazole is combined with Topiramate.]
[N07XX07, dalfampridine, Topiramate may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[A03AB15, diphemanil, The risk or severity of hyperthermia and oligohydrosis can be increased when Diphemanil is combined with Topiramate.]
[A03AB09, isopropamide, The risk or severity of hyperthermia and oligohydrosis can be increased when Isopropamide is combined with Topiramate.]
[S01FA03, methscopolamine, The risk or severity of hyperthermia and oligohydrosis can be increased when Methscopolamine is combined with Topiramate.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Topiramate is combined with Talbutal.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Topiramate is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Topiramate is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Topiramate is combined with Pyrantel.]
[J04AK01, pyrazinamide, Topiramate may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Topiramate is combined with Mepyramine.]
[C01BA01, quinidine, The risk or severity of hyperthermia and oligohydrosis can be increased when Quinidine is combined with Topiramate.]
[P01BC01, quinine, The risk or severity of adverse effects can be increased when Topiramate is combined with Quinine.]
[A02BA02, ranitidine, Topiramate may decrease the excretion rate of Ranitidine which could result in a higher serum level.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Topiramate.]
[J05AP01, ribavirin, Topiramate may decrease the excretion rate of Ribavirin which could result in a higher serum level.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Topiramate is combined with Oxitriptan.]
[N02BA05, salicylamide, Salicylamide may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[A07EC01, sulfasalazine, Sulfasalazine may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[S01BC08, salicylic acid, Salicylic acid may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[S01FA02, scopolamine, The risk or severity of hyperthermia and oligohydrosis can be increased when Scopolamine is combined with Topiramate.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Topiramate is combined with Secobarbital.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Topiramate is combined with Selegiline.]
[J01GB08, sisomicin, Topiramate may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Topiramate may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Topiramate may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be increased when combined with Topiramate.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Topiramate which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Topiramate is combined with Chloral hydrate.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Topiramate is combined with Valproic acid.]
[C01DA14, isosorbide mononitrate, Topiramate may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[D10AX03, azelaic acid, Topiramate may decrease the excretion rate of Azelaic acid which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[D11AX02, gamma-linolenic acid, The therapeutic efficacy of Topiramate can be decreased when used in combination with Gamolenic acid.]
[R03BB01, ipratropium bromide, The risk or severity of hyperthermia and oligohydrosis can be increased when Ipratropium is combined with Topiramate.]
